Saluda Medical Adds Laureen DeBuono to Board of Directors

ARTARMON, Australia, Oct. 4, 2022 /PRNewswire/ — Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced neural activation and sensing technologies, today announced the appointment of Laureen DeBuono to its board of directors and Chair of the company’s Audit Committee….Read More

Read More
Rivus Pharmaceutical Closes $132M Series B

CHARLOTTESVILLE, Va., September 22, 2022 – Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, today announced the completion of a $132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi…Read More

Read More
Arsenal Bio Closes $220M Series B

South San Francisco, Calif. – September 6, 2022 – Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced the close of a $220 million Series B financing round. New investors Softbank Vision Fund 2, Bristol-Myers Squibb Company, Byers…Read More

Read More
Rani Therapeutics Completes $45M Debt Financing

SAN JOSE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”, “the Company” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported positive topline results for the single-ascending portion of the Phase 1 clinical study of…Read More

Read More
Novartis Acquires Kedalion Therapeutics

East Hanover, N.J., June 30, 2022 — Novartis today announced that it has acquired Kedalion Therapeutics and its AcuStream™ technology, an innovative device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. The acquisition enhances the Novartis ophthalmics portfolio,…Read More

Read More